Found 212 chains in Genus chains table. Displaying 51 - 100. Applied filters: Proteins

Search results query: mitogen-activated protein kinase 1

Total Genus Sequence Length pdb Title
116 346 6frpA Crystal structure of erk2 in complex with an adenosine derivative
111 346 6fr1A Crystal structure of erk2 in complex with an adenosine derivative
118 347 6g54A Crystal structure of erk2 covalently bound to sm1-71
116 345 6fj0A Crystal structure of erk2 in complex with an adenosine derivative
108 345 6fleA Crystal structure of erk2 in complex with an adenosine derivative
110 348 6gjdA Erk2 signalling protein
112 346 6fjbA Crystal structure of erk2 in complex with an adenosine derivative
119 345 6fi3A Crystal structure of erk2 in complex with an adenosine derivative
117 346 6fjzA Crystal structure of erk2 in complex with an adenosine derivative
108 346 6fi6A Crystal structure of erk2 in complex with an adenosine derivative
112 350 6gjbA Erk2 signalling protein
111 346 6fn5A Crystal structure of erk2 in complex with an adenosine derivative
116 346 6fq7A Crystal structure of erk2 in complex with an adenosine derivative
109 347 6qagA Erk2 mini-fragment binding
106 347 6qa4A Erk2 mini-fragment binding
106 347 6qawA Erk2 mini-fragment binding
108 348 6qa1A Erk2 mini-fragment binding
110 350 6qa3A Erk2 mini-fragment binding
109 350 6q7kA Erk2 mini-fragment binding
115 347 6qaqA Erk2 mini-fragment binding
106 347 6qalA Erk2 mini-fragment binding
107 347 6qahA Erk2 mini-fragment binding
113 346 6q7sA Erk2 mini-fragment binding
113 346 6q7tA Erk2 mini-fragment binding
106 346 6fxvA Crystal structure of erk2 in complex with an adenosine derivative
107 357 3sa0A Complex of erk2 with norathyriol
110 345 5nhlA Human erk2 with an erk1/2 inhibitor
109 345 5nhvA Human erk2 with an erk1/2 inhibitor
116 348 5nhhA Human erk2 with an erk1/2 inhibitor
112 347 5lcjA In-gel activity-based protein profiling of a clickable covalent erk 1/2 inhibitor
116 350 5k4iA Crystal structure of erk2 in complex with compound 22
117 347 5hd4A Dissecting therapeutic resistance to erk inhibition rat wild type sch772984 in complex with (3r)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-n-[3-(pyridin-4-yl)-2h-indazol-5-yl]pyrrolidine-3-carboxamide
107 348 6gdqA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
107 347 6g9kA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
108 347 6ge0A Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
110 347 6g93A Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
110 350 6g91A Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
109 350 6g9aA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
115 346 6g9mA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
104 347 6g8xA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
111 347 6g9nA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
113 350 6g92A Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
102 349 6gdmA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
111 347 6g97A Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
108 350 6g9dA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
110 347 6g9hA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
105 350 6g9jA Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of erk1/2
108 339 6dcgA Discovery of mk-8353: an orally bioavailable dual mechanism erk inhibitor for oncology
108 340 6cpwA Discovery of 3(s)-thiomethyl pyrrolidine erk inhibitors for oncology
115 350 5bvdA Tetrahydropyrrolo-diazepenones as inhibitors of erk2 kinase